Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Basset

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Prognostication of survival and progression to dialysis in AA amyloidosisGiovanni Palladini, Eloisa Riva, Marco Basset, et al.
The FEBS Journal|September 5, 2021
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregationGiulia Mazzini, Stefano Ricagno, Serena Caminito, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosisPaolo Milani, Stefan Schönland, Giovanni Palladini, et al.
Hemasphere|March 25, 2025
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control studyClaudia Bellofiore, Marco Basset, Giuseppe Damiano Sanna, et al.
Clinical Chemistry and Laboratory Medicine|March 5, 2016
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosisGiovanni Palladini, Paolo Milani, Andrea Foli, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 26, 2020
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patientsPaolo Milani, Faye Sharpley, Stefan O Schönland, et al.
American Journal of Hematology|December 4, 2024
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUSSilvia Mangiacavalli, Paolo Milani, Claudio Salvatore Cartia, et al.
Blood|November 13, 2019
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosisMarco Basset, Irene Defrancesco, Paolo Milani, et al.
American Journal of Hematology|April 14, 2020
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltratePaolo Milani, Francesca Fazio, Marco Basset, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 11, 2024
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosisPaolo Milani, Francesca Fabris, Roberta Mussinelli, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Prognostication of survival and progression to dialysis in AA amyloidosisGiovanni Palladini, Eloisa Riva, Marco Basset, et al.
The FEBS Journal|September 5, 2021
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregationGiulia Mazzini, Stefano Ricagno, Serena Caminito, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosisPaolo Milani, Stefan Schönland, Giovanni Palladini, et al.
Hemasphere|March 25, 2025
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control studyClaudia Bellofiore, Marco Basset, Giuseppe Damiano Sanna, et al.
Clinical Chemistry and Laboratory Medicine|March 5, 2016
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosisGiovanni Palladini, Paolo Milani, Andrea Foli, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 26, 2020
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patientsPaolo Milani, Faye Sharpley, Stefan O Schönland, et al.
American Journal of Hematology|December 4, 2024
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUSSilvia Mangiacavalli, Paolo Milani, Claudio Salvatore Cartia, et al.
Blood|November 13, 2019
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosisMarco Basset, Irene Defrancesco, Paolo Milani, et al.
American Journal of Hematology|April 14, 2020
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltratePaolo Milani, Francesca Fazio, Marco Basset, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 11, 2024
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosisPaolo Milani, Francesca Fabris, Roberta Mussinelli, et al.
Pageof 6